Skip to Content
Merck
All Photos(1)

Documents

I2286

Sigma-Aldrich

Irbesartan

≥98% (HPLC), powder

Synonym(s):

2-Butyl-3-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one, Avapro, BMS-186295, SR-47436

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C25H28N6O
CAS Number:
Molecular Weight:
428.53
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

Assay

≥98% (HPLC)

form

powder

color

white to off-white

solubility

DMSO: >25 mg/mL

originator

Bristol-Myers Squibb
Sanofi Aventis

storage temp.

2-8°C

SMILES string

CCCCC1=NC2(CCCC2)C(=O)N1Cc3ccc(cc3)-c4ccccc4-c5nnn[nH]5

InChI

1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)

InChI key

YOSHYTLCDANDAN-UHFFFAOYSA-N

Gene Information

human ... AGTR1(185)

Looking for similar products? Visit Product Comparison Guide

General description

Irbesartan comprises bipentyl-tetrazole side chain. It is an imidazole derivative with high bioavailability and is metabolized by the enzyme cytochrome P450 2C9 isoenzyme in liver to be majorly eliminated by oxidation and glucuronidation.

Application

Irbesartan has been used as an angiotensin II receptor type 1 (ATR1) blocker in carotid atheroma tissue. It may be used to test its effect on allergic asthma in rat and mice mast cells.

Biochem/physiol Actions

Irbesartan is an angiotensin II type 1 (AT1) receptor antagonist with antihypertensive activity. It also elicits selective peroxisome proliferator-activated receptor γ (PPARγ)-modulating activity and possesses anti-inflammatory properties. Irbesartan shows protective cardiovascular effects and provides protection against chronic glomerulonephritis.

Features and Benefits

This compound is featured on the Angiotensin Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Bristol-Myers Squibb and Sanofi Aventis. To browse the list of other pharma-developed compounds, Approved Drugs, and Drug Candidates, click here.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Marie Hudson et al.
Pharmacotherapy, 27(4), 526-534 (2007-03-27)
To examine the class effect of angiotensin II receptor blockers (ARBs) on mortality in patients with heart failure who were aged 65 years or older. Retrospective population-based study. Administrative database that stores information on hospital discharge summaries for the Canadian
Jian-Ming Chen et al.
International journal of molecular sciences, 21(3) (2020-02-12)
In this study, we explored the release characteristics of analgesics, namely levobupivacaine, lidocaine, and acemetacin, from electrosprayed poly(D,L-lactide-co-glycolide) (PLGA) microparticles. The drug-loaded particles were prepared using electrospraying techniques and evaluated for their morphology, drug release kinetics, and pain relief activity.
Paula Clancy et al.
Journal of atherosclerosis and thrombosis, 23(7), 773-791 (2016-03-08)
Matrix metalloproteinases (MMPs), angiotensin II (AII) and its receptors are implicated in atherosclerotic plaque instability, however the roles of the two receptor subtypes, ATR1 and ATR2, in MMP regulation remain uncertain. In this study, we investigated the effect of ATR1
Guru Prasad Sharma et al.
International journal of radiation oncology, biology, physics, 113(1), 177-191 (2022-01-31)
Radiation-induced lung injury is a major dose-limiting toxicity for thoracic radiation therapy patients. In experimental models, treatment with angiotensin converting enzyme (ACE) inhibitors mitigates radiation pneumonitis; however, the mechanism of action is not well understood. Here, we evaluate the direct
Ross T Campbell et al.
Journal of the American College of Cardiology, 60(23), 2349-2356 (2012-11-13)
Examination of patients with reduced and preserved ejection fraction in the DIG (Digitalis Investigation Group) trials and the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) trials provides comparisons of outcomes in each of these types

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service